Investor Announcements - 2013

Interim results

16^th Sep 2013

EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2013.

Final results for the year ended 31 December 2012

18^th Mar 2013

Final results for the year ended 31 December 2012.

Establishment of EKF Molecular Diagnostics & Acquisition of 360 Genomics Limited

4^th Mar 2013

EKF Diagnostics announces that it has established a new subsidiary, EKF Molecular Diagnostics Limited (“EKF Molecular”), to focus on molecular and companion diagnostics.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

LOGISTICS: A total meltdown

EKF globally launches STAT-Site® WB β-ketone and glucose handheld analyzer

EKF obtains CE mark certification alongside CLIA waiver for easy-to-use whole blood analyzer for diabetes care programmes

EKF opens larger facility to increase production of key component for COVID-19 testing regime

EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore^® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations.

EKF fly the extra mile over Christmas

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies